| Trial Status | Recruiting |
| Dates | Date of activation: 21-Apr-10 |
| Data management at EORTC | Full |
| Phase | 3 |
| Randomized trial | Yes |
| Type | Advanced |
| Targeted Sample size | EORTC Groups: 300 - All Groups: 458 |
| Number of steps | 1 |
| Drug | Sunitinib |
| Study Staff | Axel Bex (Study Coordinator) - The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam John B.A.G. Haanen (Study Coordinator) - The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam Sandra Collette (Statistician) - EORTC Headquarters, Brussels Richard Sylvester (Statistician) - EORTC Headquarters, Brussels Linda De Prijck (Data Manager) - EORTC Headquarters, Brussels Sandrine Marreaud (Coordinating Physician) - EORTC Headquarters, Brussels Julie Hermans (Project Manager) - EORTC Headquarters, Brussels, julie.hermans( at )eortc.be, +32 27741673 Gloria Montanes (Clinical Research Associate) - EORTC Headquarters, Brussels |
| Type of cancer | Kidney |
| Participating Groups | EORTC Genito-Urinary Cancers Group(Coordinating Group) Canadian Urologic Oncology Group German Association of Urologic Oncology National Cancer Research Institute - Renal Cancer Group |
| Centers authorized by EORTC | Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet (Brussels, Belgium) - Inst. 101 Universitair Ziekenhuis Gent (Gent, Belgium) - Inst. 104 Cliniques Universitaires St. Luc (Brussels, Belgium) - Inst. 121 AZ Damiaan (Oostende, Belgium) - Inst. 130 Onze Lieve Vrouw Ziekenhuis (Aalst, Belgium) - Inst. 150 Virga Jesse Hospital (Hasselt, Belgium) - Inst. 1217 AZ Groeninge Kortrijk - Campus Loofstraat (Kortrijk, Belgium) - Inst. 1257 Queen Elizabeth II Health Sciences Centre (Halifax, Nova Scotia, Canada) - Inst. 9373 Diamond Health Care Centre (Vancouver, Canada) - Inst. 9374 Montreal General Hospital (Montreal, Canada) - Inst. 181 University Health Network - Oci / Princess Margaret Hospital (Toronto, Canada) - Inst. 754 The Ottawa Hospital, The Integrated Cancer Program- General Campus (Ottawa, Canada) - Inst. 876 CHUM - Pavillon Saint-Luc (Montreal, Quebec, Canada) - Inst. 1785 San Camillo Forlanini Hospitals (Roma, Italy) - Inst. 796 Jeroen Bosch Ziekenhuis ('s-Hertogenbosch, The Netherlands) - Inst. 22 St. Antonius Ziekenhuis (Nieuwegein, The Netherlands) - Inst. 81 The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis (Amsterdam, The Netherlands) - Inst. 301 Radboud University Nijmegen Medical Centre (Nijmegen, The Netherlands) - Inst. 304 Universitair Medisch Centrum - Academisch Ziekenhuis (Utrecht, The Netherlands) - Inst. 306 Vrije Universiteit Medisch Centrum (Amsterdam, The Netherlands) - Inst. 308 Academisch Ziekenhuis Maastricht (Maastricht, The Netherlands) - Inst. 324 University Medical Center Groningen (Groningen, The Netherlands) - Inst. 335 Academisch Medisch Centrum - Universiteit van Amsterdam (Amsterdam, The Netherlands) - Inst. 342 Barts Health NHS Trust - St. Bartholomew'S Hospital (London, United Kingdom) - Inst. 558 Royal Free Hospital (London, United Kingdom) - Inst. 598 Leeds Teaching Hospitals NHS Trust - St. James'S University Hospital (Leeds, United Kingdom) - Inst. 601 Imperial College Healthcare NHS Trust - Charing Cross Hospital (London, United Kingdom) - Inst. 603 Christie NHS Foundation Trust (Manchester, United Kingdom) - Inst. 610 Velindre NHS Trust - Velindre Cancer Centre (Cardiff, United Kingdom) - Inst. 626 University Hospitals Bristol NHS Foundation Trust - Bristol Haematology And Oncology Centre (Bristol, United Kingdom) - Inst. 664 Singelton Hospital (Swansea, United Kingdom) - Inst. 669 Royal United Hospital (Bath, United Kingdom) - Inst. 683 Basildon University Hospital (Basildon, United Kingdom) - Inst. 9174 |
| Protocol summary | Cancer.gov (PDQ) ClinicalTrials.gov |
| NCT number | NCT01099423 |
| EudraCT | |
| Protocol documents in PDF (requires password) | Study documentation |